Capital raised

Hubro Therapeutics is pleased to announce that NOK 41,1 mill has been raised in a private placement.

The funds will be used to continue the company’s development of lead candidate vaccine FMPV-1, adjuvant GM-CSF and companion diagnostics,

as well as preparing for initiation of the phase 2 study with FMPV-1/GM-CSF in MSI-colorectal cancer.

This website uses cookies to ensure you get the best experience on our website.